Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100PJWU
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥8.4bn2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.6bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.4bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥2.6bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥16.5bnat 2022-09-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥28.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-44.792021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥9.752021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥1.1bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.5bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2021-01-01 → 2021-09-30−¥21m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥506m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 372
ItemContextValueUnit
Loss on retirement of noncurrent assets elCurrentYTDDuration7000000JPY
Premium allowance of retirement elPrior1YTDDuration－JPY
Premium allowance of retirement elCurrentYTDDuration226000000JPY
Impairment loss elPrior1YTDDuration225000000JPY
Impairment loss elCurrentYTDDuration48000000JPY
Extraordinary lossPrior1YTDDuration225000000JPY
Extraordinary lossCurrentYTDDuration282000000JPY
Income before income taxesPrior1YTDDuration-2553000000JPY
Income before income taxesCurrentYTDDuration-3180000000JPY
Income taxes currentPrior1YTDDuration20000000JPY
Income taxes currentCurrentYTDDuration8000000JPY
Income taxes deferredPrior1YTDDuration-626000000JPY
Income taxes deferredCurrentYTDDuration-6000000JPY
Income taxesPrior1YTDDuration-605000000JPY
Income taxesCurrentYTDDuration1000000JPY
Profit lossPrior1YTDDuration-1947000000JPY
Profit lossCurrentYTDDuration-3182000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-1947000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-3182000000JPY
Profit lossPrior1YTDDuration-1947000000JPY
Profit lossCurrentYTDDuration-3182000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration96000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration161000000JPY
Other comprehensive incomePrior1YTDDuration96000000JPY
Other comprehensive incomeCurrentYTDDuration161000000JPY
Comprehensive incomePrior1YTDDuration-1851000000JPY
Comprehensive incomeCurrentYTDDuration-3021000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-1851000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-3021000000JPY
Write downs of inventoriesPrior1YTDDuration1642000000JPY
Write downs of inventoriesCurrentYTDDuration555000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember3022000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember5327000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember5000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8355000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration8355000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember3022000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember5327000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember5000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8355000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration8355000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1009000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass